Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Phosphoinositide 3-kinase p110δ (human) polyclonal antibody

ALX-210-747-C200 200 µg 386.00 USD
Do you need bulk/larger quantities?

Product Specification

Alternative Name:PI(3)K p110δ
Immunogen:Synthetic peptide corresponding to aa 1026-1044 (S1026WKTKVNWLAHNVSKDNRQ1044) of the C-terminal domain of human PI(3)K p110δ (phosphoinositide 3-kinase p110δ).
UniProt ID:O00329
Species reactivity:Human
Applications:ICC, IHC (PS), WB
Recommended Dilutions/Conditions:Immunocytochemistry (1:300)
Western Blot (1:1,000)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application.
Application Notes:Detects a band of ~110kDa by Western blot.
Purity Detail:Epitope-affinity purified IgG.
Quality Control:Western blot on human T cell line Jurkat.
Formulation:Liquid. In PBS containing 1mg/ml BSA and 0.1% sodium azide.
Handling:For maximum product recovery after thawing, centrifuge the vial before opening the cap. Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
Shipping:Shipped on Blue Ice
Long Term Storage:-20°C

General Literature References

p110delta, a novel phosphoinositide 3-kinase in leukocytes: B. Vanhaesebroeck, et al.; PNAS 94, 4330 (1997), Abstract; Full Text

Product Toolbox


Certificate of Analysis


By target:
PI3 kinase
By biological activity:
PI3 kinase Polyclonal antibody
By catalog section:


Technical Service
Customer Service

Related Literature

Diabetes Catalog
Diabetes Catalog
Download as PDF

Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

Technical Posters
Disease-Associated Stress Signaling
Disease-Associated Stress Signaling
Download as PDF

All new literature pieces

Recommend this page

For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2018 Enzo Life Sciences, Inc.,